NASDAQ:TCON TRACON Pharmaceuticals (TCON) Stock Forecast, Price & News $0.21 -0.01 (-5.01%) (As of 11:10 AM ET) Add Compare Share Share Today's Range$0.20▼$0.2150-Day Range$0.21▼$0.3752-Week Range$0.18▼$2.19Volume35,278 shsAverage Volume290,039 shsMarket Capitalization$6.34 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media TRACON Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside2,759.9% Upside$6.00 Price TargetShort InterestHealthy1.32% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.56) to ($1.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.66 out of 5 stars 3.3 Analyst's Opinion Consensus RatingTRACON Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, TRACON Pharmaceuticals has a forecasted upside of 2,759.9% from its current price of $0.21.Amount of Analyst CoverageTRACON Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.32% of the outstanding shares of TRACON Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverTRACON Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TRACON Pharmaceuticals has recently increased by 70.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTRACON Pharmaceuticals does not currently pay a dividend.Dividend GrowthTRACON Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TCON. Previous Next 1.1 News and Social Media Coverage News SentimentTRACON Pharmaceuticals has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for TRACON Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for TCON on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added TRACON Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TRACON Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.27% of the stock of TRACON Pharmaceuticals is held by insiders.Percentage Held by Institutions40.17% of the stock of TRACON Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for TRACON Pharmaceuticals are expected to decrease in the coming year, from ($0.56) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TRACON Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TRACON Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About TRACON Pharmaceuticals (NASDAQ:TCON) StockTRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.Read More TCON Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCON Stock News HeadlinesSeptember 20, 2023 | americanbankingnews.comTRACON Pharmaceuticals (NASDAQ:TCON) Receives New Coverage from Analysts at StockNews.comSeptember 18, 2023 | finance.yahoo.comTRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as PlannedSeptember 25, 2023 | Edge On The Street (Ad)An Unusual Way to Invest in GoldMost financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines. September 2, 2023 | finance.yahoo.com7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot PoleAugust 22, 2023 | msn.comJonesTrading Downgrades TRACON Pharmaceuticals (TCON)August 18, 2023 | finance.yahoo.comTCON Aug 2023 2.500 callAugust 16, 2023 | finanznachrichten.deTRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 15, 2023 | finance.yahoo.comQ2 2023 TRACON Pharmaceuticals Inc Earnings CallSeptember 25, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.August 14, 2023 | finance.yahoo.comTRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 3, 2023 | finance.yahoo.comTRACON to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 14, 2023July 11, 2023 | finance.yahoo.comTRACON Pharmaceuticals Announces Collection of Arbitration Award from I-Mab BiopharmaJune 20, 2023 | msn.comWhat's Going On With TRACON Pharmaceuticals Shares TodayJune 20, 2023 | finance.yahoo.comTRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal TrialJune 16, 2023 | finance.yahoo.comTRACON Pharmaceuticals to Present at the Maxim Group Healthcare Virtual ConferenceJune 15, 2023 | finance.yahoo.comTRACON Pharmaceuticals Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab BiopharmaMay 30, 2023 | finance.yahoo.comTRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual MeetingMay 12, 2023 | msn.comMaxim Group Maintains TRACON Pharmaceuticals (TCON) Buy RecommendationMay 12, 2023 | msn.comBaird Maintains TRACON Pharmaceuticals (TCON) Outperform RecommendationMay 12, 2023 | msn.comRecap: TRACON Pharma Q1 EarningsMay 11, 2023 | finance.yahoo.comQ1 2023 TRACON Pharmaceuticals Inc Earnings CallMay 10, 2023 | finance.yahoo.comTRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 10, 2023 | finance.yahoo.comTRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 3, 2023 | finance.yahoo.comTRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023May 1, 2023 | msn.comShort Volatility Alert: Tracon PharmaceuticalsApril 25, 2023 | msn.comTracon Pharmaceuticals Plunges after Unfavorable Arbitration RulingApril 25, 2023 | msn.comTracon stock slumps ~15% after I-Mab gets favorable ruling in arbitrationSee More Headlines Receive TCON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TCON Company Calendar Last Earnings8/14/2023Today9/25/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TCON CUSIPN/A CIK1394319 Webwww.traconpharma.com Phone(858) 550-0780Fax858-550-0786Employees18Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$12.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+2,658.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,140,000.00 Net MarginsN/A Pretax Margin-313.58% Return on EquityN/A Return on Assets-159.92% Debt Debt-to-Equity RatioN/A Current Ratio0.41 Quick Ratio0.41 Sales & Book Value Annual Sales$350,000.00 Price / Sales19.08 Cash FlowN/A Price / Cash FlowN/A Book Value($0.33) per share Price / Book-0.66Miscellaneous Outstanding Shares30,700,000Free Float29,082,000Market Cap$6.68 million OptionableNot Optionable Beta1.24 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Charles P. Theuer M.D. (Age 59)Ph.D., CEO, Pres & Director Comp: $803.7kMr. Scott B. Brown CPA (Age 42)M.S., Chief Financial Officer Comp: $451.64kMs. Bonne Adams M.B.A. (Age 46)Chief Operating Officer Mr. Shahe GarabedianSr. VP & Head of Quality AssuranceDr. James L. Freddo (Age 68)Chief Medical Officer Mr. Ya HuangExec. Director of Statistical ProgrammingDr. Brenda Marczi Pharm.D.Pharmd Mba, Sr. VP of Regulatory AffairsMore ExecutivesKey CompetitorsCreative Medical TechnologyNASDAQ:CELZTitan PharmaceuticalsNASDAQ:TTNPBioCardiaNASDAQ:BCDAInhibikase TherapeuticsNYSE:IKTWindtree TherapeuticsNASDAQ:WINTView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCSold 2,900 shares on 8/15/2023Ownership: 0.000%BlackRock Inc.Sold 38,109 shares on 8/11/2023Ownership: 0.945%Simplex Trading LLCSold 600 shares on 8/4/2023Ownership: 0.000%Charles TheuerBought 3,999 shares on 4/26/2023Total: $2,639.34 ($0.66/share)Opaleye Management Inc.Bought 174,508 shares on 3/9/2023Total: $240,821.04 ($1.38/share)View All Insider TransactionsView All Institutional Transactions TCON Stock - Frequently Asked Questions Should I buy or sell TRACON Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TCON shares. View TCON analyst ratings or view top-rated stocks. What is TRACON Pharmaceuticals' stock price forecast for 2023? 3 Wall Street analysts have issued twelve-month price objectives for TRACON Pharmaceuticals' shares. Their TCON share price forecasts range from $3.00 to $12.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 2,658.6% from the stock's current price. View analysts price targets for TCON or view top-rated stocks among Wall Street analysts. How have TCON shares performed in 2023? TRACON Pharmaceuticals' stock was trading at $1.49 at the beginning of 2023. Since then, TCON shares have decreased by 85.4% and is now trading at $0.2175. View the best growth stocks for 2023 here. Are investors shorting TRACON Pharmaceuticals? TRACON Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totaling 404,700 shares, an increase of 70.1% from the August 15th total of 237,900 shares. Based on an average daily volume of 473,100 shares, the short-interest ratio is presently 0.9 days. View TRACON Pharmaceuticals' Short Interest. When is TRACON Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our TCON earnings forecast. How were TRACON Pharmaceuticals' earnings last quarter? TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) released its quarterly earnings data on Monday, August, 14th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.30. The biopharmaceutical company had revenue of $9 million for the quarter. What other stocks do shareholders of TRACON Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX). When did TRACON Pharmaceuticals IPO? (TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers. What is TRACON Pharmaceuticals' stock symbol? TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON." Who are TRACON Pharmaceuticals' major shareholders? TRACON Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.95%), Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown. View institutional ownership trends. How do I buy shares of TRACON Pharmaceuticals? Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is TRACON Pharmaceuticals' stock price today? One share of TCON stock can currently be purchased for approximately $0.22. How much money does TRACON Pharmaceuticals make? TRACON Pharmaceuticals (NASDAQ:TCON) has a market capitalization of $6.68 million and generates $350,000.00 in revenue each year. The biopharmaceutical company earns $-29,140,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis. How can I contact TRACON Pharmaceuticals? TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The official website for the company is www.traconpharma.com. The biopharmaceutical company can be reached via phone at (858) 550-0780, via email at ir@traconpharma.com, or via fax at 858-550-0786. This page (NASDAQ:TCON) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TRACON Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.